Nitrosonifedipine ameliorates angiotensin II-induced vascular remodeling via antioxidative effects

[1]  H. Okayama,et al.  Temporary treatment with AT1 receptor blocker, valsartan, from early stage of hypertension prevented vascular remodeling. , 2011, American journal of hypertension.

[2]  T. Tamaki,et al.  Protective effect of photodegradation product of nifedipine against tumor necrosis factor alpha-induced oxidative stress in human glomerular endothelial cells. , 2011, The journal of medical investigation : JMI.

[3]  E. Schiffrin,et al.  Mitogen-Activated Protein Kinase–Activated Protein Kinase 2 in Angiotensin II–Induced Inflammation and Hypertension: Regulation of Oxidative Stress , 2011, Hypertension.

[4]  T. Tamaki,et al.  Antioxidant effects of photodegradation product of nifedipine. , 2011, Chemical & pharmaceutical bulletin.

[5]  A. Brasier,et al.  Aortic Adventitial Fibroblasts Participate in Angiotensin-Induced Vascular Wall Inflammation and Remodeling , 2010, Journal of Vascular Research.

[6]  M. Ueki,et al.  Role of Hypoxia-Inducible Factor 1&agr; in T Cells as a Negative Regulator in Development of Vascular Remodeling , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[7]  T. Tamaki,et al.  Angiotensin II receptor blocker attenuates PDGF-induced mesangial cell migration in a receptor-independent manner. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  浦田 将久.  Role of hypoxia-inducible factor 1α in T cells as a negative regulator in development of vascular remodeling , 2010 .

[9]  S. Kato,et al.  Androgen-androgen receptor system protects against angiotensin II-induced vascular remodeling. , 2009, Endocrinology.

[10]  T. Tamaki,et al.  Drug discovery for overcoming chronic kidney disease (CKD): development of drugs on endothelial cell protection for overcoming CKD. , 2009, Journal of pharmacological sciences.

[11]  E. Letavernier,et al.  Targeting the Calpain/Calpastatin System as a New Strategy to Prevent Cardiovascular Remodeling in Angiotensin II–Induced Hypertension , 2008, Circulation research.

[12]  Rhian M. Touyz,et al.  NADPH Oxidases, Reactive Oxygen Species, and Hypertension , 2008, Diabetes Care.

[13]  J. Sowers,et al.  NADPH Oxidase Contributes to Vascular Inflammation, Insulin Resistance, and Remodeling in the Transgenic (mRen2) Rat , 2007, Hypertension.

[14]  K. Griendling,et al.  Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. , 2007, American journal of physiology. Cell physiology.

[15]  R. Touyz,et al.  Redox signaling in hypertension. , 2006, Cardiovascular research.

[16]  Xiaoping Yang,et al.  Angiotensin II promotes smooth muscle cell proliferation and migration through release of heparin-binding epidermal growth factor and activation of EGF-receptor pathway. , 2005, Molecules and cells.

[17]  Pierre-Emmanuel Gleizes,et al.  Roles of eukaryotic ribosomal proteins in maturation and transport of pre-18S rRNA and ribosome function. , 2005, Molecular cell.

[18]  A. Nishiyama,et al.  Aldosterone Stimulates Vascular Smooth Muscle Cell Proliferation Via Big Mitogen-Activated Protein Kinase 1 Activation , 2005, Hypertension.

[19]  Y. Fujita,et al.  ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells. , 2005, Experimental cell research.

[20]  M. Yoshizumi,et al.  Dual effects of endothelin-1 (1-31): induction of mesangial cell migration and facilitation of monocyte recruitment through monocyte chemoattractant protein-1 production by mesangial cells. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[21]  L. Núñez-Vergara,et al.  Structural effects on the reactivity 1,4-dihydropyridines with alkylperoxyl radicals and ABTS radical cation. , 2004, Bioorganic & medicinal chemistry.

[22]  E. Schiffrin,et al.  Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice , 2004, Journal of hypertension.

[23]  Y. Suh,et al.  NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. , 2004, Biochemical and biophysical research communications.

[24]  T. Masaki,et al.  Ca2+ Entry Channels Involved in Contractions of Rat Aorta Induced by Endothelin-1, Noradrenaline, and Vasopressin , 2002, Journal of cardiovascular pharmacology.

[25]  M. Yoshizumi,et al.  Quercetin glucuronide prevents VSMC hypertrophy by angiotensin II via the inhibition of JNK and AP-1 signaling pathway. , 2002, Biochemical and biophysical research communications.

[26]  U. Walter,et al.  Effects of Angiotensin II Infusion on the Expression and Function of NAD(P)H Oxidase and Components of Nitric Oxide/cGMP Signaling , 2002, Circulation research.

[27]  A. Dorrance,et al.  NADH/NADPH Oxidase and Enhanced Superoxide Production in the Mineralocorticoid Hypertensive Rat , 2001, Hypertension.

[28]  L. Berliner,et al.  In vivo EPR evidence for free radical adducts of nifedipine , 1999, Magnetic resonance in medicine.

[29]  D. Harrison.  Endothelial Function and Oxidant Stress , 1997, Clinical cardiology.

[30]  P. Zahradka,et al.  Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth muscle cells. , 1997, Circulation research.

[31]  E. Fleck,et al.  Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. , 1997, Hypertension.

[32]  D. Harrison,et al.  Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.

[33]  B L Langille,et al.  Cellular and molecular biology of vascular remodeling , 1996, Current opinion in lipidology.

[34]  S M Schwartz,et al.  The intima. Soil for atherosclerosis and restenosis. , 1995, Circulation research.

[35]  P. Bohov,et al.  Effect of illuminated nifedipine, a potent antioxidant, on intestinal and vascular smooth muscles , 1995, British journal of pharmacology.

[36]  V. Mišík,et al.  Reactive radical intermediates formed from illuminated nifedipine. , 1994, Free radical biology & medicine.

[37]  V. A. Folcik,et al.  Predominance of esterified hydroperoxy-linoleic acid in human monocyte-oxidized LDL. , 1994, Journal of lipid research.

[38]  R W Alexander,et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.

[39]  B. Dixon,et al.  Bradykinin and angiotensin II: activation of protein kinase C in arterial smooth muscle. , 1994, The American journal of physiology.

[40]  K. Sugawara,et al.  High-performance liquid chromatographic determination of nifedipine and a trace photodegradation product in hospital prescriptions. , 1992, Journal of pharmaceutical and biomedical analysis.

[41]  V. Mišík,et al.  Spin-trapping and antioxidant properties of illuminated and nonilluminated nifedipine and nimodipine in heart homogenate and model system. , 1991, Molecular pharmacology.

[42]  M. Daemen,et al.  Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. , 1991, Circulation research.